Breaking News
Global News
Chola Securities in News
Sessions News
Economy News
Nifty 50
Sensex
Nifty Bank
Bankex
Nifty 100
BSE Sensex 50
Nifty Financial Services
BSE Sensex Next 50
Nifty Midcap 100
BSE Bharat 22
Nasdaq
DJIA
S&P 500
Hang Seng
Nikkei 225
Straits Times
FTSE 100
KLSE Composite
Jakarta Composite
Exchange Holiday List
Historical Returns
Top Gainers
Top Losers
52 Week High
52 Week Low
Most Active by Value
Most Active by Volume
Out Performer
Under Performer
Advances & Declines
Only Buyers and Sellers
Bulk deal
Block deal
Nifty Futures
Nifty Options
Bank Nifty Futures
Bank Nifty Options
Stock Futures
Stock Options
Increase in OI
Decrease in OI
Highest in OI
Lowest in OI
All Index Futures
Most Active Contracts
Most Active Call
Most Active Put
Solutions
Platforms
Research
More
Markets
Become a partner
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Rexulti Tablets, of Otsuka Pharmaceutical Company (Otsuka).
Brexpiprazole tablets have an estimated market size of $ 2 billion for twelve months ending September 2024 according to IQVIA.
Alembic has a cumulative total of 220 ANDA approvals (194 final approvals and 26 tentative approvals) from USFDA.
Alembic Pharmaceuticals is in the business of the development, manufacturing, and marketing of pharmaceutical products, i.e., formulations and active pharmaceutical ingredients.
The pharmaceutical company's consolidated net profit increased 12.3% to Rs 153.41 crore in Q2 FY25 as compared to Rs 136.56 crore posted in Q2 FY24. Revenue from operations grew 3.3% year on year (YoY) to Rs 1,647.98 crore in the quarter ended 30 September 2024.
The scrip shed 0.44% to currently trade at Rs 1,004.75 on the BSE.
Powered by Capital Market - Live News
on Chola Securities Mobile & Web App.
Stay organised, informed & in control while accessing your portfolio, reports, trading tools and service requests—all in one seamless platform.